Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:CYTX

Cytori Therapeutics (CYTX) Stock Price, News & Analysis

Cytori Therapeutics logo

About Cytori Therapeutics Stock (NASDAQ:CYTX)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$1.13
$1.36
50-Day Range
$0.20
$0.21
52-Week Range
$0.20
$0.75
Volume
3.41 million shs
Average Volume
915,302 shs
Market Capitalization
$25.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cytori Therapeutics, Inc. is a late stage cell therapy company, which engages in the development of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. It offers the Cytori Nanomedicine, Cytori Cell Therapy, and other clinical trials. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in San Diego, CA.

Remove Ads
Receive CYTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytori Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CYTX Stock News Headlines

Cytori Cell Research Institute Inc.
Checkpoint Therapeutics Inc (CKPT)
DOGE Social Security bombshell?
Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social Security, finding what he says is widespread fraud across the agency.
Sage Therapeutics Inc SAGE
5 Biotech Stocks Under $10 Blasting Higher
8 Stocks Under $10 Ripping Higher
See More Headlines

CYTX Stock Analysis - Frequently Asked Questions

Cytori Therapeutics Inc (NASDAQ:CYTX) posted its quarterly earnings results on Tuesday, May, 14th. The biotechnology company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.20) by $0.02. The biotechnology company earned $0.70 million during the quarter. Cytori Therapeutics had a negative net margin of 242.60% and a negative trailing twelve-month return on equity of 272.70%.

Shares of Cytori Therapeutics reverse split on Thursday, May 24th 2018. The 1-10 reverse split was announced on Wednesday, May 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 23rd 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cytori Therapeutics investors own include Regulus Therapeutics (RGLS), Inovio Pharmaceuticals (INO), Shire (SHPG), Bank of America (BAC), BCE (BCE), Celldex Therapeutics (CLDX) and Micron Technology (MU).

Company Calendar

Last Earnings
5/14/2019
Today
3/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical & Medical Instruments
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CYTX
Fax
N/A
Employees
37
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-12,630,000.00
Net Margins
-242.60%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.67 million
Price / Cash Flow
N/A
Book Value
$0.35 per share
Price / Book
3.31

Miscellaneous

Free Float
N/A
Market Cap
$25.71 million
Optionable
Not Optionable
Beta
1.96
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:CYTX) was last updated on 3/31/2025 by MarketBeat.com Staff
From Our Partners